PET-guided first-line nivolumab plus chemotherapy for advanced Hodgkin lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The FINISH protocol gives all newly diagnosed patients with advanced or bulky classical Hodgkin lymphoma induction immunochemotherapy including nivolumab plus EACOPD-14, then uses an interim PET-CT after two cycles to guide next steps. Patients with a good PET response receive de-escalated consolidation with Nivo-AVD followed by nivolumab alone, while those with incomplete responses receive continued or intensified therapy according to further PET results. The study also collects blood for circulating tumor DNA (ctDNA) analysis at set time points to compare molecular response with PET findings and explore early residual disease detection. Primary goals are to maintain or improve efficacy while reducing long-term toxicity through PET-guided de-escalation and early checkpoint inhibitor integration.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed written informed consent prior to any study-specific procedures
* Histologically confirmed classical Hodgkin lymphoma (cHL)
* Newly diagnosed disease, Ann Arbor stage IIB (bulky), III, or IV
* At least one measurable lesion ≥15 mm in the longest diameter (by CT)
* Age between 18 and 60 years (inclusive)
* ECOG performance status 0-2
* PET-CT performed at baseline
* No prior chemotherapy, radiotherapy, or immunotherapy for lymphoma
* Adequate organ function, including:
* Serum creatinine ≤ 0.2 mmol/L
* Absence of severe cardiac, pulmonary, hepatic, or renal dysfunction
* Ability to comply with the study protocol and scheduled visits

Exclusion Criteria:

* Active hepatitis B or C infection
* Positive test for HIV
* Pregnancy or breastfeeding
* Prior or active autoimmune disease requiring systemic therapy
* Vaccination with a live vaccine within 30 days prior to first nivolumab dose
* History of non-infectious pneumonitis requiring corticosteroids
* Prior malignancy (except for adequately treated basal cell carcinoma or cervical carcinoma in situ)
* Congestive heart failure, unstable angina, recent myocardial infarction, or severe cardiac arrhythmias
* Severe renal impairment (serum creatinine \> 0.2 mmol/L), unless lymphoma-related
* Severe hepatic dysfunction, unless directly related to lymphoma
* Severe pneumonia with respiratory failure or hypoxemia not corrected within 2-3 days
* Sepsis or hemodynamic instability
* Life-threatening bleeding events (e.g., gastrointestinal or cerebral hemorrhage)
* Cachexia (total serum protein \< 35 g/L), unless due to lymphoma-related liver damage
* Decompensated diabetes mellitus
* Any somatic or psychiatric condition that, in the investigator's judgment, precludes informed consent or study participation

Where it's running

• National Medical Research Center for Hematology
  Moscow, Russia Recruiting

Study contacts

• Study coordinator: Anna A Kravtsova, MD
• Email: kravtsovaanna95@gmail.com
• Phone: +74956122361

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nivolumab plus AVD for newly diagnosed early-stage non-bulky classical Hodgkin lymphoma in young patients

  This study tests whether nivolumab added to AVD can help children, teens, and young adults with newly diagnosed early-stage non-bulky Hodgkin lymphoma.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07551583

• Nivolumab with AVD versus PET-adapted BEACOPP-like for advanced classical Hodgkin lymphoma

  This trial will test whether starting treatment with low-dose nivolumab plus AVD works better than a PET-adapted BEACOPP-like approach for adults (18–60) with advanced classical Hodgkin lymphoma.

  Recruiting at 3 sites Phase 2 St. Petersburg State Pavlov Medical University · Moscow and 2 other locations · NCT07234487

• BrECADD for stage 2B–III classical Hodgkin lymphoma

  This tests the BrECADD chemotherapy combination in adults 18–60 with stage 2B (with risk factors) or stage III classical Hodgkin lymphoma and uses ctDNA to help track treatment response.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07002216

• Combining nivolumab and ruxolitinib for treating relapsed Hodgkin lymphoma

  This study is testing if combining two drugs, nivolumab and ruxolitinib, can safely help people with relapsed Hodgkin lymphoma feel better.

  Recruiting at 3 sites Phase 1/2 Big Ten Cancer Research Consortium · Chicago, Illinois and 5 other locations · NCT03681561

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

• Intratumoral fluorescent nivolumab before surgery in head and neck cancer

  This study tests injecting fluorescently labeled nivolumab directly into head and neck tumors to see if it is safe and whether it reaches nearby lymph nodes before surgical removal.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07741565

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.